Therefore, DPYSL2 may be a promising marker for evaluating AML and an effective target for treating AML, which is of great significance to improving the AML prognosis system and the targeting of DPYSL2 to treat AML in the future. Here, DPYSL2 is linked to acute myeloid leukemia.